• Questions? +1 (732) 747-1007
  • ir@americancryostem.com
  • Physicians
  • Licensing & Partners
American CryoStem, Stem Cell TherapyAmerican CryoStem, Stem Cell TherapyAmerican CryoStem, Stem Cell TherapyAmerican CryoStem, Stem Cell Therapy
  • SERVICES
    • HOW IT WORKS
    • COSMETIC CRYO-FAT
    • ADULT STEM CELLS
  • PRODUCTS
    • TISSUE HARVESTING SYSTEM
    • STEM CELL MEDIAS
    • STEM CELL LINES
  • OUR SCIENCE
    • LONG COVID CLINICAL TRIAL
  • INVESTORS
    • ABOUT US
    • STOCK INFORMATION
    • PRESS RELEASES
    • OUR LEADERSHIP
    • LICENSING PARTNERS
  • NEWS
  • CONTACT

American CryoStem To Present At Upcoming BioNJ 2014 International BioPartnering Conference

April 8, 2014

EATONTOWN, N.J. — (MEDIA ADVISORY) — April 8, 2014 — American CryoStem Corporation (OTCQB: CRYO), a leading strategic developer, marketer, and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced that the Company has been invited to present at the BioNJ International BioPartnering Conference to be held at The Westin Princeton at Forrestal Village in Princeton, NJ on April 10, 2014.

The Conference will include partnering sessions, company presentations, and speaker sessions with top-level executives from leading biotechnology, pharmaceutical, and research industries. Participants will have an opportunity to showcase their companies, meet potential funders, and network with other biotechnology companies from New Jersey and around the world.

“We have advanced our standardized stem cell platform and development activities to the point where we are actively seeking strategic collaborations,” commented Anthony Dudzinski, COO of American CryoStem. “This conference will allow us to present our cutting-edge stem cell platform to leading pharmaceutical and biotechnology companies that have the capability to significantly accelerate our development of cellular therapies and treatments,” continued Dudzinski.

International BioPartnering Conference –

EVENT AT A GLANCE

WHO: Anthony Dudzinski – COO

WHEN: Thursday, April 10, 2014 11:00 to 11:15 AM

WHERE: The Westin Princeton at Forrestal Village
201 Village Boulevard
Princeton, NJ

About BioNJ
With more than 300 member companies, BioNJ is singularly focused on the growth and prosperity of New Jersey’s biotechnology cluster. Founded in 1994 by New Jersey industry CEOs, BioNJ serves as the voice of biotechnology companies located in New Jersey, seeks to advance their economic growth and development and works to encourage new and established companies from around the world to locate in New Jersey. BioNJ represents companies engaged in biopharmaceutical, biomedical, bioagricultural and bioremedial endeavors.

About American CryoStem Corporation
A pioneer in the fields of Regenerative and Personalized Medicine, American CryoStem operates a state-of-the-art, FDA-registered, clinical laboratory dedicated to processing, bio-banking and development of cellular applications using autologous adipose (fat) tissue and adipose derivered stem cells (ADSCs). Through its scientific efforts, the Company has built a strong, strategic portfolio of intellectual property, patent applications, and proprietary operating processes that form its core standardized cellular platform. For more information, please visit www.americancryostem.com and www.acslaboratories.com. You can also find us on Facebook and Twitter.

Share

Related posts

January 6, 2023

American CryoStem Announces FDA Approval of IND to Commence Phase I Clinical Trial for Long COVID/Post-Acute Sequelae of SARS-CoV-2 (PASC)


Read more
December 22, 2022

American CryoStem Announces the Addition of Agustin Legido, MD, PhD, MBA to its Advisory Board


Read more
March 4, 2022

American CryoStem Announces Patient Treatment Status for its Phase I Clinical Trial for Post-Concussion Syndrome (PCS)


Read more

About American CryoStem Corporation

American CryoStem Corporation (OTC:CRYO), is a clinical-stage biotechnology company, global licensor and a pioneer in autologous (one’s own) cellular processing and therapies. The Company's centralized laboratory model and patented foundational “CryoStem Platform” is a best-in-class, end-to-end cellular therapy solution to treat injuries, disorders and chronic diseases through a single adipose-tissue (fat) harvest and ATCELLBank™ cryopreservation. We are dedicated to helping the world’s physicians, hospitals, and clinics improve clinical outcomes by developing and delivering effective leading-edge stem cell therapies that improve patient health and quality of life.

© 2021 American CryoStem Corporation | A Publicly Traded Company (CRYO)
  • Physicians
  • Licensing & Partners